- Home
- HOV vs TVTX Comparison
HOV vs TVTX Comparison
Compare HOV & TVTX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- HOV
- TVTX
- Stock Information
- Founded
- HOV 1959
- TVTX 2008
- Country
- HOV United States
- TVTX United States
- Employees
- HOV N/A
- TVTX N/A
- Industry
- HOV Homebuilding
- TVTX Biotechnology: Pharmaceutical Preparations
- Sector
- HOV Consumer Discretionary
- TVTX Health Care
- Exchange
- HOV Nasdaq
- TVTX Nasdaq
- Market Cap
- HOV 1.3B
- TVTX 1.3B
- IPO Year
- HOV N/A
- TVTX N/A
- Fundamental
- Price
- HOV $175.51
- TVTX $18.26
- Analyst Decision
- HOV Hold
- TVTX Buy
- Analyst Count
- HOV 1
- TVTX 13
- Target Price
- HOV $155.00
- TVTX $23.46
- AVG Volume (30 Days)
- HOV 63.6K
- TVTX 1.4M
- Earning Date
- HOV 12-03-2024
- TVTX 10-31-2024
- Dividend Yield
- HOV N/A
- TVTX N/A
- EPS Growth
- HOV 48.22
- TVTX N/A
- EPS
- HOV 31.75
- TVTX N/A
- Revenue
- HOV $2,912,312,000.00
- TVTX $203,447,000.00
- Revenue This Year
- HOV N/A
- TVTX $62.45
- Revenue Next Year
- HOV N/A
- TVTX $59.30
- P/E Ratio
- HOV $5.42
- TVTX N/A
- Revenue Growth
- HOV 5.68
- TVTX 57.08
- 52 Week Low
- HOV $86.61
- TVTX $5.12
- 52 Week High
- HOV $240.34
- TVTX $20.33
- Technical
- Relative Strength Index (RSI)
- HOV 45.94
- TVTX 55.85
- Support Level
- HOV $164.70
- TVTX $16.86
- Resistance Level
- HOV $188.60
- TVTX $19.51
- Average True Range (ATR)
- HOV 8.94
- TVTX 1.10
- MACD
- HOV 0.40
- TVTX -0.19
- Stochastic Oscillator
- HOV 42.73
- TVTX 40.35
About HOV Hovnanian Enterprises Inc.
Hovnanian Enterprises Inc conducts all of its homebuilding and financial services operations . The company designs, constructs, markets, and sells single-family detached homes, attached townhomes and condominiums, urban infill, and active lifestyle homes in planned residential developments. It has two distinct operations: homebuilding and financial services. Its homebuilding operations are divided geographically into three segments; Northeast which includes Delaware, Maryland, New Jersey, Ohio, Pennsylvania, Virginia and West Virginia; Southeast which includes Florida, Georgia and South Carolina; and West which includes Arizona, California and Texas. The firm generates maximum revenue from West Segment.
About TVTX Travere Therapeutics Inc.
Travere Therapeutics Inc is a biopharmaceutical company. The company is focused on identifying, developing and delivering life-changing therapies to people living with rare kidney, liver, and metabolic diseases. Its pipeline candidate, sparsentan, is an investigational product candidate in late-stage development for focal segmental glomerulosclerosis (FSGS) and IgA nephropathy (IgAN) - rare kidney disorders that often cause end-stage kidney disease.